What A Terpene Number On A Certificate Of Analysis Means

Terpenes are volatile compounds, which is why you can smell them and why they are measured the way they are. The usual method is gas chromatography: a sample is vaporised, carried through a column that separates its components by how readily they move, and each component is identified and quantified as it emerges, either by mass spectrometry or by flame ionisation.

Two consequences follow, and both are routinely missed.

The first is that every result has a limit of quantification, below which the instrument can say a compound is present but not reliably say how much. A compound reported as not detected has not been proven absent. It was below the threshold of the method used on the day.

The second is that a profile usually names a dozen or two compounds out of a far larger number actually present. The percentages beside those names do not sum to the material's total volatile content, and were never meant to.

A terpene profile is not a fixed property of a cultivar the way a genome is. It is an outcome, and a long list of things upstream of the laboratory move it: growing conditions, light, nutrition, the point in development at which the material was harvested, and how it was dried and cured afterwards.

This is ordinary plant chemistry and it is not a defect. The same cultivar grown in two rooms, or in one room in two seasons, will assay differently. Published analyses of essential-oil crops show the pattern plainly: the dominant constituent of citrus peel oil has been reported anywhere between roughly 65% and 96% of the oil depending on species, maturity and extraction method.

Practically, batch-to-batch variation in a profile is expected, and a profile quoted without its batch is not information.

This is the part almost nothing written for patients mentions, and it is the part with a practical consequence.

Volatile compounds leave. That is what volatile means. A terpene profile begins declining from the moment material is packaged, and the rate depends on temperature, on how much air is in the container, on how often it is opened, and on time.

Oxidation runs alongside evaporation, and it changes composition rather than merely reducing it. Monoterpenes react with atmospheric oxygen to form hydroperoxides and related products. This is established well enough in fragrance chemistry that European cosmetics regulation places a peroxide value limit on monoterpene raw materials rather than trusting the compound name alone, and one published analysis of an air-exposed terpene ester found oxidation products accumulating to 37% of the material after 42 weeks.

So a certificate describes the material on its test date. It is a photograph rather than a specification of what is in your hand now, and the gap between the two widens with every week and every opening of the container.

Read as a quality document rather than as a prediction, it does real work.

It is evidence that the material was characterised at all, by a laboratory, against a method. It allows one batch to be compared with another on a like-for-like basis. It speaks to the identity and consistency requirements that the Australian standard governing this class of material imposes. And read across time, a declining profile is exactly how degradation shows itself as a number.

Those are not small things. They are the difference between a supply chain that measures itself and one that asserts.

"The research is limited" is a sentence that ends thinking rather than starting it. The question here is specific, and it is worth setting out properly, because it has two halves that are usually run together.

The question is whether the quantity of an individual constituent in a material predicts anything about how that material behaves in a person. For that to hold, one of two mechanisms has to be doing work, and they are separable.

The first is pharmacokinetic. A constituent present at a few per cent would have to change how the material as a whole is absorbed, distributed or cleared — by altering membrane permeability, by competing for the same metabolising enzymes, by changing the rate at which something crosses from lung or gut into blood. Monoterpenes are small, lipophilic and cross membranes readily, which is precisely why they are studied as penetration enhancers in unrelated fields. The mechanism is not implausible on its face. What is missing is quantification: at the concentrations a profile actually reports, nobody has established whether the effect is meaningful or vanishingly small.

The second is pharmacodynamic. The constituent would have to act somewhere itself. Here the in-vitro literature is substantial rather than thin — individual terpenes have measurable activity at ion channels, at GABA-A receptors, at enzymes including acetylcholinesterase — and those are real measurements, not hand-waving. The unresolved step is the one that decides the fate of most in-vitro pharmacology: whether the concentration that produces an effect in a dish is ever approached in tissue at a realistic exposure.

So the position is not that the question has been answered in the negative. It is that it has two halves, each partly explored, neither closed. That is a different thing, and it is the more interesting one.

If the question is that clearly framed, the obvious response is to go and run the study. It is worth understanding why that is difficult, because the obstacles are methodological rather than a matter of funding or appetite.

Blinding is the first. These are, by definition, the compounds you can smell. A trial comparing two profiles cannot easily conceal from the participant which one they have, and expectancy effects on subjective outcomes are substantial. Trials of aromatic preparations have worked around this with odour-matched comparators, but the workarounds are imperfect and they narrow what can be asked.

Dose equivalence is the second. A profile reports a proportion of a material, not a quantity delivered to a person. Converting between the two requires knowing how much material is used, what fraction of each constituent survives the route into the body, and how that fraction differs between routes. Those conversion factors are themselves largely unmeasured, which means even a well-designed trial struggles to state its own exposure in terms a profile would recognise.

Covariance is the third, and it is the one that bites hardest on reading a profile. To attribute an outcome to a named constituent you must vary that constituent while holding the others still. In plant material the constituents move together — the growing conditions that raise one tend to shift several. Only a constructed preparation lets you vary one at a time, and a constructed preparation is no longer the thing whose profile you set out to interpret.

That is the shape of the problem. It is tractable, it is genuinely hard, and nobody should expect it to be settled as a by-product of routine batch testing.

Is this certificate for the batch actually supplied, or a representative one for the product in general? Those are different documents, and only the first describes the material in front of you.

What was the test date, and how long ago was that? Everything in the section above follows from the answer.

Was total volatile content reported, or only the named compounds? A list of fifteen compounds is not a complete account of the material.

What was the limit of quantification for the method? Without it, not detected is an incomplete statement.

None of those are difficult questions. They are the ones worth putting to anyone who supplies you, and the ones a careful reader works through before deciding whether a batch is what it claims to be.